Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

33.53

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

0.18

EPS Last/This Y

0.23

EPS This/Next Y

0.25

Price

5.49

Target Price

7

Analyst Recom

2.43

Performance Q

-16.69

Relative Volume

2.86

Beta

0.83

Ticker: RXRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08RXRX4.390.370.30329131
2025-05-09RXRX4.310.380.37333309
2025-05-12RXRX4.630.390.19320644
2025-05-13RXRX4.510.380.22325728
2025-05-14RXRX4.30.380.35329782
2025-05-15RXRX4.260.380.35338017
2025-05-16RXRX4.560.380.46348145
2025-05-19RXRX4.510.410.36324751
2025-05-20RXRX4.550.410.21328698
2025-05-21RXRX4.110.410.22330085
2025-05-22RXRX4.140.410.13336193
2025-05-23RXRX4.070.400.19337062
2025-05-27RXRX4.390.400.10323650
2025-05-28RXRX4.390.380.10341451
2025-05-29RXRX4.440.370.13349567
2025-05-30RXRX4.160.370.24351562
2025-06-02RXRX4.360.380.24342536
2025-06-03RXRX4.390.380.22346642
2025-06-04RXRX4.910.380.09349927
2025-06-05RXRX4.570.350.12379336
2025-06-06RXRX5.490.360.07385950
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08RXRX4.3813.8- -1.41
2025-05-09RXRX4.3313.8- -1.44
2025-05-12RXRX4.6413.8- -1.44
2025-05-13RXRX4.5111.0- -1.46
2025-05-14RXRX4.3013.8- -1.44
2025-05-15RXRX4.2613.8- -1.44
2025-05-16RXRX4.5611.0- -1.46
2025-05-19RXRX4.5111.0- -1.46
2025-05-20RXRX4.5511.0- -1.46
2025-05-21RXRX4.0911.0- -1.46
2025-05-22RXRX4.1411.0- -1.46
2025-05-23RXRX4.0711.0- -1.46
2025-05-27RXRX4.3911.0- -1.46
2025-05-28RXRX4.4011.0- -1.46
2025-05-29RXRX4.4511.0- -1.46
2025-05-30RXRX4.1811.0- -1.46
2025-06-02RXRX4.3611.0- -1.46
2025-06-03RXRX4.3911.0- -1.46
2025-06-04RXRX4.9111.0- -1.46
2025-06-05RXRX4.5711.0- -1.46
2025-06-06RXRX5.4911.0- -1.46
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08RXRX-0.3815.6231.06
2025-05-09RXRX-0.3815.6230.70
2025-05-12RXRX-0.3814.5130.25
2025-05-13RXRX-0.3814.5130.25
2025-05-14RXRX-0.3814.5130.25
2025-05-15RXRX-0.3414.5130.45
2025-05-16RXRX-0.3014.5130.45
2025-05-19RXRX-0.309.0930.25
2025-05-20RXRX-0.309.0929.97
2025-05-21RXRX-0.319.0929.97
2025-05-22RXRX-0.319.0929.97
2025-05-23RXRX-0.319.0929.97
2025-05-27RXRX-0.31-1.9829.96
2025-05-28RXRX-0.31-1.9833.53
2025-05-29RXRX-0.31-1.9833.53
2025-05-30RXRX-0.31-1.9833.53
2025-06-02RXRX-0.31-1.3433.53
2025-06-03RXRX-0.31-1.3433.53
2025-06-04RXRX-0.31-1.3433.53
2025-06-05RXRX-0.31-1.3433.53
2025-06-06RXRX-0.31-1.3433.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

-0.31

Institutional Transactions

-1.34

Beta

0.83

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

20

Fair Value

Quality Score

29

Growth Score

55

Sentiment Score

38

Actual DrawDown %

87.2

Max Drawdown 5-Year %

Target Price

7

P/E

Forward P/E

PEG

P/S

37.32

P/B

2.39

P/Free Cash Flow

EPS

-1.78

Average EPS Est. Cur. Y​

-1.46

EPS Next Y. (Est.)

-1.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-961.32

Relative Volume

2.86

Return on Equity vs Sector %

-85.6

Return on Equity vs Industry %

-67.6

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

Recursion Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 800
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today
news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance
stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market
stock prices RXRX premarket after hours
ticker RXRX fair value insiders trading